Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Aaron C, Loh, Tracy J, Kwang, Xue Lin, Tan, Gek San, Lim, Kiat Hon, Tan, Daniel S W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987308/
https://www.ncbi.nlm.nih.gov/pubmed/33776501
http://dx.doi.org/10.2147/LCTT.S263610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987308/
https://www.ncbi.nlm.nih.gov/pubmed/33776501
http://dx.doi.org/10.2147/LCTT.S263610

Ejemplares similares